GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Shiller PE Ratio

Kaken Pharmaceutical Co (TSE:4521) Shiller PE Ratio : 8.70 (As of May. 01, 2024)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Shiller PE Ratio?

As of today (2024-05-01), Kaken Pharmaceutical Co's current share price is 円3477.00. Kaken Pharmaceutical Co's E10 for the quarter that ended in Dec. 2023 was 円399.45. Kaken Pharmaceutical Co's Shiller PE Ratio for today is 8.70.

The historical rank and industry rank for Kaken Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

TSE:4521' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.02   Med: 12.37   Max: 21.95
Current: 8.53

During the past years, Kaken Pharmaceutical Co's highest Shiller PE Ratio was 21.95. The lowest was 8.02. And the median was 12.37.

TSE:4521's Shiller PE Ratio is ranked better than
91.37% of 533 companies
in the Drug Manufacturers industry
Industry Median: 24.9 vs TSE:4521: 8.53

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Dec. 2023 was 円68.841. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is 円399.45 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kaken Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Kaken Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Shiller PE Ratio Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.47 13.89 11.49 10.04 9.42

Kaken Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.61 9.42 9.09 8.80 8.40

Competitive Comparison of Kaken Pharmaceutical Co's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Shiller PE Ratio falls into.



Kaken Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kaken Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=3477.00/399.45
=8.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=68.841/106.8000*106.8000
=68.841

Current CPI (Dec. 2023) = 106.8000.

Kaken Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 54.533 95.700 60.858
201406 62.380 98.000 67.981
201409 72.260 98.500 78.349
201412 95.700 97.900 104.400
201503 60.758 97.900 66.281
201506 152.090 98.400 165.073
201509 149.251 98.500 161.827
201512 184.687 98.100 201.066
201603 24.369 97.900 26.584
201606 140.050 98.100 152.470
201609 136.454 98.000 148.707
201612 157.876 98.400 171.353
201703 98.700 98.100 107.453
201706 133.810 98.500 145.085
201709 133.750 98.800 144.580
201712 148.500 99.400 159.555
201803 54.168 99.200 58.318
201806 100.160 99.200 107.834
201809 120.680 99.900 129.015
201812 136.000 99.700 145.685
201903 88.826 99.700 95.152
201906 121.650 99.800 130.183
201909 120.910 100.100 129.003
201912 154.110 100.500 163.771
202003 98.054 100.300 104.408
202006 98.180 99.900 104.961
202009 87.970 99.900 94.046
202012 96.540 99.300 103.832
202103 64.486 99.900 68.940
202106 87.780 99.500 94.220
202109 88.460 100.100 94.381
202112 93.170 100.100 99.406
202203 -18.430 101.100 -19.469
202206 76.910 101.800 80.688
202209 81.430 103.100 84.352
202212 84.970 104.100 87.174
202303 -98.978 104.400 -101.253
202306 66.990 105.200 68.009
202309 41.190 106.200 41.423
202312 68.841 106.800 68.841

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kaken Pharmaceutical Co  (TSE:4521) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Kaken Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines